BR0311642A - Formulação de divalproex de sódio de liberação aumentada - Google Patents

Formulação de divalproex de sódio de liberação aumentada

Info

Publication number
BR0311642A
BR0311642A BR0311642-5A BR0311642A BR0311642A BR 0311642 A BR0311642 A BR 0311642A BR 0311642 A BR0311642 A BR 0311642A BR 0311642 A BR0311642 A BR 0311642A
Authority
BR
Brazil
Prior art keywords
formulation
increased release
release sodium
divalproex
sodium divalproex
Prior art date
Application number
BR0311642-5A
Other languages
English (en)
Inventor
Pratik Kumar
Garish Kumar Jain
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0311642A publication Critical patent/BR0311642A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

"FORMULAçãO DE DIVALPROEX DE SóDIO DE LIBERAçãO AUMENTADA". A presente invenção se refere a uma composição farmacêutica de liberação aumentada compreendendo ácido valpróico, um sal farmaceuticamente aceitável, éster, ou amida do mesmo ou divalproex de sódio.
BR0311642-5A 2002-06-07 2003-06-06 Formulação de divalproex de sódio de liberação aumentada BR0311642A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN615DE2002 2002-06-07
PCT/IB2003/002173 WO2003103635A1 (en) 2002-06-07 2003-06-06 Extended release formulation of divalproex sodium

Publications (1)

Publication Number Publication Date
BR0311642A true BR0311642A (pt) 2005-03-01

Family

ID=29727199

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311642-5A BR0311642A (pt) 2002-06-07 2003-06-06 Formulação de divalproex de sódio de liberação aumentada

Country Status (9)

Country Link
US (1) US20040037880A1 (pt)
EP (1) EP1513503A1 (pt)
JP (1) JP2005533774A (pt)
CN (1) CN1671363A (pt)
AU (1) AU2003240164A1 (pt)
BR (1) BR0311642A (pt)
CA (1) CA2488691A1 (pt)
MX (1) MXPA04012198A (pt)
WO (1) WO2003103635A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1921838A (zh) * 2004-02-19 2007-02-28 兰贝克赛实验室有限公司 双丙戊酸钠的缓释药物组合物
BRPI0512988A (pt) 2004-07-08 2008-04-22 Novo Nordisk As método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
WO2006025029A2 (en) * 2004-08-31 2006-03-09 Ranbaxy Laboratories Limited Extended release composition of divalproex
US20120178810A1 (en) * 2006-09-11 2012-07-12 Tailor Prakash Boya Extended release formulation of an antiepileptic agent
US20080081069A1 (en) * 2006-09-28 2008-04-03 Lupin Limited Novel controlled release formulations of divalproex sodium
CA2599082A1 (en) * 2007-08-27 2009-02-27 Ping I. Lee Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds
CN102138911B (zh) * 2011-03-28 2012-12-12 孙卫东 一种双丙戊酸钠缓释片及其制备方法
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
EP2882427A2 (en) * 2012-05-08 2015-06-17 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN105616338B (zh) * 2016-01-29 2019-05-21 北京达因高科儿童药物研究院有限公司 一种丙戊酸钠口服缓释制剂及其制备方法
WO2017163267A1 (en) * 2016-03-23 2017-09-28 Sun Pharmaceutical Industries Ltd. An improved method of administering divalproex
WO2017163268A2 (en) * 2016-03-23 2017-09-28 Sun Pharmaceutical Industries Ltd. A sustained release pharmaceutical dosage form of divalproex
CN111012753A (zh) * 2020-01-07 2020-04-17 仁和堂药业有限公司 一种提高丙戊酸钠片剂稳定性的方法
CN113304117B (zh) * 2021-04-30 2023-05-12 山东京卫制药有限公司 一种丙戊酸钠缓释片的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IL72381A (en) * 1983-07-20 1988-03-31 Sanofi Sa Pharmaceutical composition based on valproic acid
US6419953B1 (en) * 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) * 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US20020143058A1 (en) * 2001-01-24 2002-10-03 Taro Pharmaceutical Inductries Ltd. Process for preparing non-hygroscopic sodium valproate composition

Also Published As

Publication number Publication date
CA2488691A1 (en) 2003-12-18
WO2003103635A1 (en) 2003-12-18
AU2003240164A1 (en) 2003-12-22
CN1671363A (zh) 2005-09-21
US20040037880A1 (en) 2004-02-26
MXPA04012198A (es) 2005-04-08
JP2005533774A (ja) 2005-11-10
EP1513503A1 (en) 2005-03-16

Similar Documents

Publication Publication Date Title
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
HK1076605A1 (en) Formulations
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
NZ597260A (en) Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone
PA8469401A1 (es) Derivados biciclicos del acido hidroxamico
UY27320A1 (es) Nuevas composiciones farmacéuticas
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
YU76503A (sh) Farmaceutski aktivni estri uridina
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
UA100966C2 (ru) Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
DK1390378T3 (da) Farmaceutisk aktive uridin estere
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
PT885014E (pt) Composicoes farmaceuticas contendo polimeros orto ester tamponados
NO20024237D0 (no) Farmasöytiske formuleringer
BR0311327A (pt) Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
CO5560554A2 (es) Composicion farmaceutica que comprende lumiracoxib
DK1228758T3 (da) Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom
AR030630A1 (es) Composiciones farmaceuticas
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
UA102111C2 (uk) Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
TW200505429A (en) Pharmaceutical composition
WO2005079753A3 (en) Extended release pharmaceutical compositions of divalproex sodium
CA2373962A1 (en) Immediate release medicinal compositions for oral use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.